A Randomised Double-blind, Placebo Controlled, Single Ascending and Repeat Dose, First Time in Human Study in Healthy Participants and Stable Asthmatics to Assess Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder
Latest Information Update: 23 Feb 2024
At a glance
- Drugs GSK 3923868 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 26 Sep 2022 Status changed from recruiting to completed.
- 10 Jun 2022 Planned End Date changed from 25 May 2022 to 15 Jun 2022.
- 10 Jun 2022 Planned primary completion date changed from 25 May 2022 to 15 Jun 2022.